Recursion to Showcase AI-Driven Drug Discovery at NVIDIA GTC
Event summary
- Recursion Pharmaceuticals will be featured in HighRes’ Lightning Talk at NVIDIA GTC, March 16-19, 2026.
- The talk, moderated by Stacie Calad-Thomson of NVIDIA, will focus on AI agents, robotics, and digital twins in drug discovery.
- Ira Hoffman, CEO of HighRes, will discuss collaboration with Recursion on self-driving, high-throughput labs.
- Recursion operates one of the most sophisticated integrated wet and dry labs for AI drug discovery.
- Recursion’s BioHive-2 supercomputer, backed by NVIDIA, processes millions of multi-omic data points weekly.
The big picture
Recursion’s participation in NVIDIA GTC underscores the growing intersection of AI and biotech, where automation and robotics are transforming drug discovery. The collaboration with HighRes highlights a strategic shift towards self-driving labs, potentially setting a new industry standard. As AI continues to permeate biotech, companies like Recursion are at the forefront of leveraging accelerated computing to drive therapeutic advancements.
What we're watching
- Technological Integration
- How Recursion’s collaboration with HighRes will affect the pace of AI-driven drug discovery.
- Market Differentiation
- Whether Recursion can sustain its lead in AI-powered biotech through its supercomputing capabilities.
- Industry Adoption
- The pace at which self-driving labs become standard in the biotech sector.
Related topics